$3.33
▼ $-0.07
(-2.06%)
Vol 481K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$106.8M
ROE
76.6%
Margin
-32.9%
D/E
401.02
Beta
1.60
52W
$1–$7
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
77.8%
Buy Rating
Price Chart
Similar Stocks
FATE
Fate Therapeutics Inc
$113.3M
SPRO
Spero Therapeutics Inc
$131.3M
CBUS
Cibus Inc
$94.5M
BDTX
Black Diamond Therapeutics Inc
P/E 6.4
$138.4M
KLRS
Kalaris Therapeutics Inc
$141.3M
EQ
Equillium Inc
$94.4M
HUMA
Humacyte Inc
$185.4M
IMDX
Insight Molecular Diagnostics Inc
$215.0M
PEPG
PepGen Inc
$447.6M
GNLX
Genelux Corp
$165.9M
Earnings
Beat rate: 60.0%
Next Report
May 11, 2026
EPS Estimate: $1.76
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $1.76 | — | — |
| Dec 2025 | $-1.07 | $-0.31 | +$0.76 |
| Sep 2025 | $2.02 | $1.94 | $-0.08 |
| Jun 2025 | $1.38 | $-1.00 | $-2.38 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $26.8M | $24.1M | $25.7M | $30.2M | $34.2M |
| Net Income | — | -$45.9M | -$25.3M | -$28.0M | $63.9M | -$10.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | 76.6% | 76.6% | 76.6% | 76.6% | 76.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -108.8% | -162.7% | -162.7% | -162.7% | -32.9% | -32.9% |
| Gross Margin | 99.1% | 99.4% | 99.4% | 99.4% | 98.9% | 98.9% |
| D/E Ratio | — | 401.02 | 401.02 | 401.02 | 401.02 | 401.02 |
| Current Ratio | 0.06 | 0.06 | 0.06 | 0.06 | 0.47 | 0.47 |
Key Ratios
ROA (TTM)
-16.6%
P/S (TTM)
1.00
P/B
24.0
EPS (TTM)
$-2.08
CF/Share
$-0.81
Rev Growth 3Y
-29.5%
52W High
$7.34
52W Low
$1.38
$1.38
52-Week Range
$7.34
Financial Health
Free Cash Flow
-$16.6M
Net Debt
$52.9M
Cash
$3.0M
Total Debt
$55.9M
As of Dec 31, 2025
How does AGEN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
AGEN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.0
▼
92%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
24.0
▲
876%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
AGEN profitability vs Biotechnology peers
ROE
76.6%
▲
214%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-32.9%
▲
89%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
98.9%
▲
26%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-16.6%
▲
64%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
AGEN financial health vs Biotechnology peers
D/E ratio
401.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
0.5
▼
89%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.6
▲
65%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
AGEN fundamentals radar
AGEN
Peer median
Industry
AGEN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AGEN vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
ARMEN GARO H.
Chief Executive Officer · Mar 20
3983 shs
ARMEN GARO H.
Chief Executive Officer · Mar 06
4994 shs
ARMEN GARO H.
Chief Executive Officer · Feb 20
4829 shs
ARMEN GARO H.
Chief Executive Officer · Feb 06
5027 shs
ARMEN GARO H.
Chief Executive Officer · Jan 23
4562 shs
ARMEN GARO H.
Chief Executive Officer · Jan 09
3780 shs
Last 90 days
Top Holders
Top 5: 14.63%Vanguard Group Inc
7.37%
$9.6M
Siren, L.L.C.
2.77%
$3.6M
Acadian Asset Management. L…
1.62%
$2.1M
Blackrock Inc.
1.45%
$1.9M
Renaissance Technologies, L…
1.42%
$1.8M
As of Dec 31, 2025
Latest News
Got $5,000? 5 Agentic AI Growth Stocks to Buy Before Wall Street …
Yahoo Finance · Apr 05
Birmingham city council doubles agency spending during bin strikes
The Guardian · Apr 03
Rivian Just Earned Another $1 Billion Investment From Volkswagen. Here's Why That's …
Nasdaq · Apr 03
Estate agents accuse Rightmove of charging excessive fees
BBC Business · Apr 01
Agent begged Epstein to have sex with model, emails show
BBC Business · Mar 29